ClinicalTrials.gg
RecruitingNCT07731490EDIT-HFUpdated Jul 28, 2026

Early Detection and IntervenTion in Heart Failure

An interventional study of Intervention bundle comprising increased awareness, early diagnostics, and early treatment to improve HF prognosis. in Heart Failure (HF), sponsored by University Hospital, Basel, Switzerland. Recruiting at 21 sites in 9 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Dec 2025, registered Jul 2026).
  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18,000
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Heart Failure by University Hospital, Basel, Switzerland — 2 open to participants now, 3 under way, none of them phase 3. Heart Failure · University Hospital, Basel, Switzerland.

Started
2025
with 1 other
No phase
5 of 11
2 open now
Registered
11th of 11
by date

Among the 11 studies in Heart Failure by University Hospital, Basel, Switzerland, this one is one of 2 that started in 2025, is one of 5 with no phase, and was the 11th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

2 of the 11 studies in Heart Failure by University Hospital, Basel, Switzerland are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Heart Failure by University Hospital, Basel, Switzerland, or all of them as a file.
02

Study summary

Heart failure (HF) occurs when the heart is no longer able to pump blood effectively throughout the body. This leads to symptoms that gradually worsen over time and are often mistaken for normal signs of aging. Because of its insidious onset, early detection is challenging. Both patients and healthcare professionals are often insufficiently aware of the early signs and symptoms of HF, resulting in delayed diagnosis. Consequently, timely initiation of treatments that could slow disease progression, improve quality of life, and reduce hospitalizations is often missed. Although a simple blood test measuring NT-proBNP levels can facilitate the early diagnosis of HF, it is not routinely used in clinical practice.

The aim of this study is to evaluate whether a combined strategy for the early diagnosis and treatment of HF can reduce hospitalizations. This strategy includes:

  1. increasing awareness of HF among patients and physicians,
  2. using NT-proBNP testing for the early detection of HF in high-risk patients, and
  3. promptly initiating guideline-directed HF treatment when the diagnosis is confirmed.

The researchers will assess whether this strategy effectively reduces hospitalizations due to acute heart failure over an 18-month follow-up period.

Read the detailed description

Heart failure (HF) is a significant global health issue, affecting approximately 64 million individuals worldwide and resulting in over a million hospitalizations annually in Europe and the US. This imposes substantial healthcare costs exceeding $100 billion yearly, with about 70% attributed to acute hospitalizations. The aging population contributes to a rising burden, as HF is often diagnosed late, even in well-funded healthcare settings. Recent insights from studies, including the ongoing BASEL VIII study, challenge the assumption that undetected HF is primarily a failure to detect HF in primary care, revealing a high prevalence of undetected HF even among patients treated by cardiologists. This research initiative revealed that among patients ≥ 65 years, only 3% had known HF, while 29% had undetected HF. Similar observations were also noted in various high-risk settings worldwide, suggesting a surprisingly high rate of undetected HF in clinical practice. Late diagnosis is driven by gradual symptom development, non-specific symptoms often attributed to aging, insensitive clinical signs, and inadequate utilization of B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) testing, the recommended tools for HF diagnosis. The misconception that HF competes with other cardiac diagnoses, rather than complementing them, further contributes to delayed diagnosis. Emerging evidence supports a strategy combining increased awareness, active surveillance using NT-proBNP testing for early HF diagnosis, and prompt treatment with approved evidence-based therapies to reduce HF hospitalizations. However, such intervention bundles are not systematically applied, as no randomized controlled trial (RCT) has ever investigated the efficacy of such structured interventions on hard outcomes. This research initiative aims to assess the effectiveness of an intervention bundle comprising increased awareness, early diagnostics, and early treatment to improve HF prognosis. The study aims to fill critical gaps and evaluate patient-centred outcomes, including hospitalization for acute HF, and health economic implications by using routine clinical data and the standard operating procedures as part of routine clinical practice in the participating sites. By addressing these challenges, the initiative seeks to enhance patient outcomes, reduce the burden on healthcare systems, and contribute to advancing HF care. The bundle intervention, comprising an educational program, guidelines-directed diagnostics, and guidelines-supported management, represents a proactive implementation of best clinical practice. As this proactive approach is not routinely implemented in real-world clinical dynamics, this study primarily focuses on accompanying the implementation of the intervention bundle and contributing valuable data regarding its efficacy. At the same time, the intervention is expected to offer a number of potential benefits for the patients, their health care providers, and the society in general. This will be achieved by a better understanding of the HF problem among patients and medical staff, better adherence to guidelines-supported best clinical practices, and the potential avoidance of hospitalisations due to acute HF.

03

Conditions studied

  • Heart Failure (HF)

Browse trials for

Keywords

  • NT-proBNP
  • Stepped-Wedge
  • Undetected Heart Failure
  • Heart Failure
  • Implementation Science
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • General consent (GC) has not been rejected.
  • Age ≥ 65 years.
  • Elective percutaneous coronary intervention* (PCI), pulmonary vein isolation* (PVI), pacemaker implantation* (PM, no cardiac resynchronisation), transcatheter aortic valve intervention* (TAVI), major non-cardiac surgery* or presenting with tachyarrhythmia to the emergency department (ED) (without a diagnosis of HF within 24h).

    • Exclusion criteria are assessed on day 1 after the procedure

Exclusion criteria

Exclusion Criteria:

  • Systolic blood pressure ≤ 95 mmHg
  • Estimated (GFR) \<30 mL/min/1.73 m2.
  • Dementia documented in the medical history.
  • cancer in the medical history.
  • Previously enrolled in this study.
  • Known HF.
  • Known allergies, , or intolerance to SGLT2 Inhibitors / Loop Diuretics / MRA or is .
  • Non-resident in the country of the recruiting site
  • Incapacity of the patient to make judgements
  • Patients not hospitalized overnight
  • Patients requiring intensive care unit (ICU) or intermediate care (IMC) stay beyond 11:00 a.m. on the first postoperative day or any post-interventional stroke unit stay until 8:00 a.m. on the first postoperative day.
  • Patients died prior to postinterventional day 1 (8:00 a.m.)
  • Severe aortic or mitral stenosis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
18,000 participants (estimated)

Study arms

  • No intervention
    Phase I
  • Other
    Phase II

    Intervention

    Other: Intervention bundle comprising increased awareness, early diagnostics, and early treatment to improve HF prognosis.

Interventions

  • OtherIntervention bundle comprising increased awareness, early diagnostics, and early treatment to improve HF prognosis.

    The study aims to fill critical gaps and evaluate patient-centred outcomes, including hospitalization for acute HF, and health economic implications by using routine clinical data and the standard operating procedures as part of routine clinical practice in the participating sites.

06

What researchers measure

Primary outcomes

  1. Acute HF event

    Time from the index procedure to an acute HF event or follow-up date, together with binary variable indicating the occurrence of an acute Hf event. Acute HF event during index hospitalization is defined as acute HF severe enough to require admission to an intensive/intermediate care unit, non-invasive ventilation, or treatment with at least 40mg furosemide IV.

    Time frame: 18 months after intervention

Secondary outcomes

  1. CV death or acute HF event

    Time from index hospitalisation to acute HF event, CV death or follow-up date, together with binary variable indicating the occurrence of acute HF event or CV death.

    Time frame: 18 months

  2. Hierarchical ordinal composite of CV death, acute HF hospitalization, acute HF during index hospitalization, and no event

    Hierarchical ordinal composite of CV death, acute HF hospitalization, acute HF during index hospitalization, and no event (analyzed using the Finkelstein-Schoenfeld win ratio framework. Ties will be resolved according to the predefined event hierarchy. The effect measure will be the win ratio with 95% confidence intervals and two-sided p-values).

    Time frame: 18 months

  3. All-cause death

    Time from index hospitalisation to hospitalization for acute HF, death, or follow-up date, together with binary variable indicating the occurrence of hospitalization for acute HF or death.

    Time frame: 18 months

  4. Cardiovascular death

    Time from index hospitalisation to CV death or follow-up date, together with binary variable indicating CV death.

    Time frame: 18 months

  5. All-cause hospitalizations

    Time from index hospitalisation to hospitalization for acute HF, death, or follow-up date, together with binary variable indicating the occurrence of hospitalization for acute HF or death.

    Time frame: 18 months

  6. Changes in medical treatment between the index hospitalisation

    Categorical variables indicating changes in specific medical treatments. Changes in medication list (dosage, active pharmaceutical ingredient) during the periods of 1) before index presentation until discharge and 2) after discharge from the index hospitalization up to the 18-month follow-up period measured from the time of the intervention

    Time frame: 18 months

  7. Change in kidney function

    Standard blood tests obtained during routine clinical care like serum creatinine indicating changes in the kidney function.

    Time frame: 18 months

  8. Health economic outcomes: cost of patient management

    Cost of patient treatment within 18 months after the index hospitalisation, from different perspectives: hospital real costs perspective, full institutional perspective (considering real costs and reimbursements), healthcare payer perspective.

    Time frame: 18 months

  9. Health economic outcome: cost-effectiveness in terms of cost per hospitalization for acute HF avoided

    Cost of patient treatment within 18 months after the index hospitalisation and number of hospitalizations for acute HF within 18 months after the index hospitalisation.

    Time frame: 18 months

Other outcomes

  1. Outcomes for implementation

    Feasibility and Appropriateness of the implementation strategy according to Weiner et. al.

    Time frame: 18 months

  2. Prevalence of undetected / untreated / suboptimal treated HF patients overall and in the different medical settings

    Continuous variable representing the proportion of patients in the entire study population, this includes patients as well with exclusions criteria.

    Time frame: 18 months

  3. Ratio between previously known and undetected HF overall and in the different medical settings, and the corresponding number needed to screen to detect one patient with undetected HF

    Continuous variable representing the proportion of newly diagnosed HF patients to previously diagnosed HF cases again assed in the overall population, this includes patients as well with exclusions criteria.

    Time frame: 18 months

07

Study locations

2 of 21 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Apr 2028, 28 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 28 months is close to that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Jul 28, 2026
StartActual
Dec 3, 2025
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2030
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07731490
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Dec 3, 2025
Primary completion
Apr 2028 (estimated)
Completion
Apr 2030 (estimated)
Last update
Jul 28, 2026

Study contacts

Christian Müller, Prof. Dr.
Contact
Christian.Mueller@usb.ch
+41 61 328 65 49
Sonja Horvat, Dr.
Contact
sonja.horvat-csoti@usb.ch

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion